We refer to our letter dated 23rd August 2022 informing you about the 'Official Action Indicated' OAI status of the Company's Monroe, North Carolina (USA) manufacturing facility by US FDA following the US FDA inspection conducted between April 04 to May 19, 2022. We wish to inform you that the US FDA has now issued a warning letter to the Monroe facility. The Company had done a voluntary recall of all its products from this site in August 2021 and since then has not been commercializing any product from this site. Hence, the warning letter will have no impact on the existing revenues. Glenmark continues to cooperate with the US FDA and is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality and compliant manufacturing standards at all of its facilities across the globe.